Diagnostic strategies for nosocomial pneumonia

被引:10
|
作者
Soto, Graciela J. [1 ]
机构
[1] Univ So Calif, Div Pulm & Crit Care Med, Los Angeles, CA 90033 USA
关键词
clinical pneumonia infection score; hospital-acquired pneumonia; procalcitonin; sTREM-1; ventilator-associated pneumonia;
D O I
10.1097/MCP.0b013e3280ef6941
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of review This review describes advances in clinical and microbiological modalities for diagnosis of nosocomial pneumonia and the role of biological markers. Recent findings Serial assessments with the clinical pulmonary infection score identifies nonsurvivors and allows discontinuation of antibiotics when there is low suspicion of pneumonia. Studies evaluating its clinical utility show mixed results. A meta-analysis revealed that an invasive approach does not affect mortality but reduces costs, antibiotic exposure, and multidrug resistance. In contrast to these findings, a recent trial comparing nonquantitative endotracheal aspirate and quantitative bronchoalveolar lavage cultures showed similar clinical outcomes and antibiotic utilization. The role of quantitative endotracheal aspirate for diagnosis of pneumonia not related to mechanical ventilation was recently evaluated. Procalcitonin and soluble triggering receptor expressed on myeloid cells-1 aid in diagnosis, identify sepsis related to ventilator-associated pneumonia and patients with worst outcomes. Summary The diagnostic modality chosen depends on availability, personnel experience, and the patient's clinical status. Recent guidelines support the use of quantitative cultures in an integrated clinical and microbiological algorithm. The decision to adjust antibiotics involves clinical reassessment and interpretation of culture results. Biological markers have a potential role as screening and prognostic tools.
引用
收藏
页码:186 / 191
页数:6
相关论文
共 50 条
  • [21] Nosocomial Acinetobacter pneumonia
    Luna, Carlos M.
    Aruj, Patricia K.
    RESPIROLOGY, 2007, 12 (06) : 787 - 791
  • [22] Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia
    Motos, Ana
    Yang, Hua
    Yang, Minlan
    Torres, Antoni
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (12) : 1439 - 1448
  • [23] Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia
    Jean, Shio-Shin
    Chang, Yin-Chun
    Lin, Wei-Cheng
    Lee, Wen-Sen
    Hsueh, Po-Ren
    Hsu, Chin-Wan
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
  • [24] Procalcitonin Kinetics and Nosocomial Pneumonia in Older Patients
    Shi, Yan
    Xu, Ying-chun
    Rui, Xi
    Zhang, Hong-min
    Wang, Yao
    Du, Wei
    RESPIRATORY CARE, 2014, 59 (08) : 1258 - 1266
  • [25] THE STUDY OF NOSOCOMIAL PNEUMONIA IN THE ICU AT SUNPATHONG HOSPITAL
    Siriprakaisil, Oraphan
    JOURNAL OF HEALTH RESEARCH, 2008, 22 (01) : 43 - 48
  • [26] The role of viruses in nosocomial pneumonia
    Chiche, Laurent
    Forel, Jean-Marie
    Papazian, Laurent
    CURRENT OPINION IN INFECTIOUS DISEASES, 2011, 24 (02) : 152 - 156
  • [27] Emerging drugs for nosocomial pneumonia
    Liapikou, Adamantia
    Torres, Antoni
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (03) : 331 - 341
  • [28] Comparing current US and European guidelines for nosocomial pneumonia
    Kelly, Daire N.
    Martin-Loeches, Ignacio
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (03) : 263 - 270
  • [29] Nosocomial pneumonia: Current etiology and impact on antimicrobial therapy
    Javier Gamazo, Julio
    Javier Candel, Francisco
    Gonzalez del Castillo, Juan
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2023, 36 : 9 - 14
  • [30] Telavancin: A Review of Its Use in Patients with Nosocomial Pneumonia
    Scott, Lesley J.
    DRUGS, 2013, 73 (16) : 1829 - 1839